Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Chairman Thomas Gad sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $30.90, for a total value of $123,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Thomas Gad also recently made the following trade(s):

  • On Monday, December 16th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $31.54, for a total value of $126,160.00.
  • On Monday, December 2nd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $32.48, for a total value of $129,920.00.
  • On Monday, November 18th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $28.85, for a total value of $115,400.00.
  • On Monday, November 4th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $30.01, for a total value of $120,040.00.
  • On Friday, October 18th, Thomas Gad sold 7,250 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $16.71, for a total value of $121,147.50.
  • On Monday, October 21st, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $31.65, for a total value of $126,600.00.

Y-mAbs Therapeutics stock traded down $0.12 during mid-day trading on Wednesday, reaching $29.84. 17,452 shares of the company were exchanged, compared to its average volume of 195,200. Y-mAbs Therapeutics, Inc has a twelve month low of $18.60 and a twelve month high of $34.49. The firm’s 50-day simple moving average is $31.98 and its two-hundred day simple moving average is $27.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a market cap of $1.20 billion, a PE ratio of -19.68 and a beta of 1.14.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.16). As a group, equities research analysts anticipate that Y-mAbs Therapeutics, Inc will post -2.34 EPS for the current year.

A number of research firms have weighed in on YMAB. Zacks Investment Research cut Y-mAbs Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Y-mAbs Therapeutics in a research report on Thursday, December 12th. JPMorgan Chase & Co. began coverage on Y-mAbs Therapeutics in a research report on Tuesday, December 24th. They set an “overweight” rating and a $39.00 price objective for the company. Cowen began coverage on Y-mAbs Therapeutics in a research report on Thursday, December 12th. They set a “buy” rating for the company. Finally, Guggenheim began coverage on Y-mAbs Therapeutics in a research report on Wednesday, November 27th. They set a “buy” rating and a $40.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $38.20.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in Y-mAbs Therapeutics by 212.6% during the 2nd quarter. BlackRock Inc. now owns 1,153,831 shares of the company’s stock worth $26,387,000 after acquiring an additional 784,672 shares during the period. Cormorant Asset Management LP lifted its holdings in shares of Y-mAbs Therapeutics by 39.8% in the 2nd quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $22,870,000 after buying an additional 284,518 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Y-mAbs Therapeutics by 16.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 748,351 shares of the company’s stock valued at $17,115,000 after buying an additional 108,054 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 72.0% in the 2nd quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock valued at $11,196,000 after buying an additional 205,021 shares during the period. Finally, State Street Corp lifted its holdings in shares of Y-mAbs Therapeutics by 9.9% in the 3rd quarter. State Street Corp now owns 353,935 shares of the company’s stock valued at $9,224,000 after buying an additional 31,878 shares during the period. 33.08% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: Trading based on a resistance level

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.